If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
A notable and unusual building in the area is the so-called "Fetta di Polenta" (lit. 'polenta slice'), formerly known as Casa Scaccabarozzi. This building is where Corso San Maurizio meets Via Giulia di Barolo, and it is one of the most peculiar examples of Turin architecture: a thin trapezoid 27 m (89 ft) wide on Via Giulia Di Barolo, 5 m (16 ft) on Corso San Maurizio and just 0.70 m (2 ft 4 in) wide on the opposite end. It was designed in 1840 by Alessandro Antonelli for his wife, Francesca Scaccabarozzi. The curious name comes from the shape of the palace, which resembles a "slice of polenta", and also because it is painted with an ochre colour. In the surroundings, in Via Vanchiglia 8 (although in downtown and not really in Vanchiglia anymore), there is another trapezoid house, albeit with less extreme design: similarly, this building is nicknamed "Fetta di Formaggio" (lit. 'cheese slice'), built in 1832 for the rich Marchese Birago di Vische by the architect Antonio Talentino. Other notable buildings are the town public baths, eclectic building built in 1905 (Corso Regina Margherita crossing Via Vanchiglia), and theTeatro della Caduta theatre, opened in 2003 in Via Michele Buniva 23, which with its 45 seats is the smallest theatre in Turin and among the smallest theatres in Europe. In Corso Regina Margherita, another notable building is the former Opera pia Reynero, a charitable organisation. The building was built in 1892.
Originally this research on alternative forms of DNA was driven by the question of how life evolved on earth and why RNA and DNA were selected by (chemical) evolution over other possible nucleic acid structures. Two hypotheses for the selection of RNA and DNA as life's backbone are either they are favored under life on Earth's conditions, or they were coincidentally present in pre-life chemistry and continue to be used now. Systematic experimental studies aiming at the diversification of the chemical structure of nucleic acids have resulted in completely novel informational biopolymers. So far a number of XNAs with new chemical backbones or leaving group of the DNA have been synthesized, e.g.: hexose nucleic acid (HNA); threose nucleic acid (TNA), glycol nucleic acid (GNA) cyclohexenyl nucleic acid (CeNA). The incorporation of XNA in a plasmid, involving 3 HNA codons, has been accomplished already in 2003. This XNA is used in vivo (E coli) as template for DNA synthesis. This study, using a binary (G/T) genetic cassette and two non-DNA bases (Hx/U), was extended to CeNA, while GNA seems to be too alien at this moment for the natural biological system to be used as template for DNA synthesis. Extended bases using a natural DNA backbone could, likewise, be transliterated into natural DNA, although to a more limited extent. Aside being used as extensions to template DNA strands, XNA activity has been tested for use as genetic catalysts.
The BPC solicited bids for the restaurant's space, leasing it in January 2025 to a branch of the Jean-Georges restaurant, which planned to renovate the space for $12 million; the Bryant Park Grill's owner sued the BPC in April 2025 to prevent Jean-Georges from using its space. After a judge granted a temporary injunction, Bryant Park Grill indicated that it would not move out when its lease expired that month, which led to litigation over the restaurant's continued occupancy of its space.
== Habitat and Niche == This species is found in the Philippines, Australia, western and central Indian Ocean, Indonesia, Malaya and New Caledonia. These sponges are sessile filter feeders, with a very important role in the ecosystem. Giant Barrel Sponges filter a tremendous amount of water throughout their lifespan (some living up to 2000 years) which increases water clarity, controls algae, and affects coral populations. These sponges also serve as a habitat for many other species such as other invertebrates, benthic fish, bacteria, and cyanobacteria.
== Background == Porous inorganic solids have found great utility as catalysts and sorption media because of their large internal surface area, i.e. the presence of voids of controllable dimensions at the atomic, molecular, and nanometer scales. With increasing environmental concerns worldwide, nanoporous materials have become more important and useful for the separation of polluting species and the recovery of useful ones. In recent years there has been great progress in applying environmentally friendly zeolites in heterogeneous reaction catalysis. The reason for their success is related to their specific features in converting molecules having kinetic diameter below 1 nm, but they become inadequate when reactants with sizes above the dimensions of the pores have to be processed. Research efforts to synthesize zeolites with larger pore diameter, high structural stability and catalytic activity have not given the expected results yet.
Sources: en.wikipedia.org
Arsenal financed moves for Granit Xhaka and Shkodran Mustafi in mid-2016 for a combined £65 million, rendering the pair one of Arsenal's most expensive ever signings, as Wenger hoped to guide the club to their first league title win in over thirteen years the following season. Although Arsenal began strongly in the league, losing only once until December, back-to-back defeats to Everton and Manchester City resulted in Arsenal losing their stronghold on the league. Wenger also served a four-match touchline ban and had to pay a £25,000 fine after pushing referee Anthony Taylor during a win at home against Burnley. Further defeats to Chelsea and Liverpool all but rendered Arsenal out of the title race, and left qualification to the Champions League threatened by March. On 30 April, Arsenal lost to main rivals Tottenham which had confirmed the latter had finished above them in the Premier League for the first time since the 1994–95 FA Premier League season. The following month also saw them fail to finish in the top four since the 1996–97 FA Premier League season. On 27 May, Wenger became the most successful manager in the history of the FA Cup as Arsenal beat Premier League winners Chelsea 2–1 at Wembley through goals from Alexis Sánchez and Aaron Ramsey. The victory represented a further record for Wenger, as Arsenal too, became the most successful club in the competition's history as they won the competition for the 13th time. Four days following the win, Wenger signed a contract extension until 2019.
In a meeting of the Quadrilateral Security Dialogue on the implications of the 2022 Russian invasion of Ukraine for the region, President Biden noted India's abstention, saying that most global allies were united against Russia. Speaking to the US Senate Foreign Relations Committee, US diplomat Donald Lu said the Biden administration was still considering sanctions against India over its S-400 deal with Russia, and its abstention at the UN. However, the Biden administration has ruled out secondary sanctions against India for its considerable oil imports or defence engagement from Russia.
In mammals, blood is in equilibrium with lymph, which is continuously formed in tissues from blood by capillary ultrafiltration. Lymph is collected by a system of small lymphatic vessels and directed to the thoracic duct, which drains into the left subclavian vein, where lymph rejoins the systemic blood circulation.
Concanavalin A (ConA) is a lectin (carbohydrate-binding protein) originally extracted from the jack-bean (Canavalia ensiformis). It is a member of the legume lectin family. It binds specifically to certain structures found in various sugars, glycoproteins, and glycolipids, mainly internal and nonreducing terminal α-D-mannosyl and α-D-glucosyl groups. Its physiological function in plants, however, is still unknown. ConA is a plant mitogen, and is known for its ability to stimulate mouse T-cell subsets giving rise to four functionally distinct T cell populations, including precursors to regulatory T cells; a subset of human suppressor T-cells is also sensitive to ConA. ConA was the first lectin to be available on a commercial basis, and is widely used in biology and biochemistry to characterize glycoproteins and other sugar-containing entities on the surface of various cells. It is also used to purify glycosylated macromolecules in lectin affinity chromatography, as well as to study immune regulation by various immune cells.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.